021-51111890
购物车（0）
sales@molnova.cn
Fosinopril sodium
CAS No. 88889-14-9
Fosinopril sodium ( SQ 28,555 )
产品货号. M16421 CAS No. 88889-14-9
Fosinopril Sodium 是血管紧张素转换酶 (ACE) 抑制剂的酯前药。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥275 | 有现货 |
|
| 10MG | ￥381 | 有现货 |
|
| 25MG | ￥527 | 有现货 |
|
| 50MG | ￥915 | 有现货 |
|
| 100MG | ￥1158 | 有现货 |
|
| 200MG | ￥1750 | 有现货 |
|
| 500MG | ￥2932 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Fosinopril sodium
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Fosinopril Sodium 是血管紧张素转换酶 (ACE) 抑制剂的酯前药。
-
产品描述Fosinopril Sodium is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension and some types of chronic heart failure.(In Vitro):Fosinopril (0, 1, 10, 33, 100μM; 30 min) partially inhibits the cosedimentation of liposomes and recombinant LPLA2.Fosinopril (250 nM) shows no inhibition of the soluble esterase activity of LPLA2.Fosinopril (0.372, 0.744, 1.116 μM) displays a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM.(In Vivo):Fosinopril (orally; 4.67 mg/kg; 4 weeks) downregulates the creatine kinase (CK) and lactate dehydrogenase (LDH) levels and against cardiac dysfunction and structural alteration.Fosinopril (orally; 4.67 mg/kg; 4 weeks) suppresses cleaved-caspase 3 expression and myocardial apoptosis in AMI rat model.
-
体外实验Fosinopril (0, 1, 10, 33, 100μM; 30 min) partially inhibits the cosedimentation of liposomes and recombinant LPLA2.Fosinopril (250 nM) shows no inhibition of the soluble esterase activity of LPLA2.Fosinopril (0.372, 0.744, 1.116 μM) displays a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM.
-
体内实验Fosinopril (orally; 4.67 mg/kg; 4 weeks) downregulates the creatine kinase (CK) and lactate dehydrogenase (LDH) levels and against cardiac dysfunction and structural alteration.Fosinopril (orally; 4.67 mg/kg; 4 weeks) suppresses cleaved-caspase 3 expression and myocardial apoptosis in AMI rat model. Animal Model:HF post-acute myocardial infarction (AMI) rat model (SPF-grade Sprague-Dawley (SD) rats, 265 ± 15 g) Dosage:4.67 mg/kg Administration:p.o.; 4 weeks Result:Against cardiac dysfunction and structural alteration and suppressed apoptosis.
-
同义词SQ 28,555
-
通路Endocrinology/Hormones
-
靶点RAAS
-
受体ACE
-
研究领域Cardiovascular Disease
-
适应症——
化学信息
-
CAS Number88889-14-9
-
分子量586.65
-
分子式C30H45NO7P·Na
-
纯度>98% (HPLC)
-
溶解度Ethanol: 4 mg/mL (6.83 mM); Water: 117 mg/mL (199.78 mM)
-
SMILESCCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2C[C@@H](C[C@H]2C(=O)[O-])C3CCCCC3.[Na+]
-
化学全称sodium;(2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylate
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
-
Alunacedase alfa
Alunacedase alfa (APN-01) is a soluble angiotensin-converting enzyme 2 (hrsACE2) with antiviral activity that reduces the competitive entry of SARS-CoV-2 into cell membranes bound to ACE2. alunacedase alfa mimics ACE2 in vivo and can be used to study novel coronavirus infections, pulmonary hypertension and acute lung injury. Alunacedase alfa mimics ACE2 in vivo and can be used to study novel coronavirus infections, pulmonary hypertension and acute lung injury.
-
Zofenopril (calcium)
Zofenopril Calcium(SQ26991) 是一种抗氧化剂，可作为血管紧张素转换酶抑制剂。 ACE 佐芬普利是一种前药，设计用于进行代谢水解，产生活性游离巯基化合物佐芬普利拉，它是一种血管紧张素转换酶 (ACE) 抑制剂。
-
Zabicipril
Zabicipril is a novel orally available angiotensin-converting enzyme inhibitor, a prodrug with antihypertensive activity following in vivo de-esterification.
